Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
December 11, 2025
Foley Viewpoints
Antitrust Risks and Compliance Strategies in Intellectual Property Portfolio Management
This article analyzes how intellectual property portfolio management can simultaneously promote innovation and present potential…
December 11, 2025
Foley Viewpoints
CARB Releases Proposed Regulations for SB 261 and 253
On December 9, 2025, the California Air Resources Board (CARB) released its proposed regulatory text for the initial regulations…
December 11, 2025
Innovative Technology Insights
OCC Issues Another Crypto-Friendly Interpretive Letter: Permissibility of Riskless Principal Crypto-Assets Transactions
On December 9, 2025, the Office of the Comptroller of the Currency (OCC) issued Interpretive Letter 1188 (IL 1188), confirming that a national bank is permitted, as part of the business of banking, to engage in riskless principal crypto-assets transactions.